In mid-January, the U.S. Environmental Protection Agency (EPA) approved requests from two southern states (Georgia and Tennessee) asking for an emergency exemption that would allow them to aerosolize selected indoor spaces with an antiviral “air treatment” called Grignard Pure.
Grignard Pure is a nanoparticle-based product. Its active ingredient is a substance called triethylene glycol (TEG).
The EPA’s approval slid in under Section 18 of the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which allows the agency to green-light pesticides for unregistered uses in defined geographic areas for up to a year during public health emergencies deemed “urgent” and “non-routine.”
Since last summer, Children’s Health Defense (CHD) has raised urgent questions about the presence of PEG in the nanoparticle-based mRNA vaccines developed by Pfizer and Moderna, authorized by the U.S. Food and Drug Administration (FDA) for emergency use against COVID.
In a Dec. 14 press release and in letters to leaders at the Department of Health and Human Services (HHS), the FDA and the National Institute of Allergy and Infectious Diseases (NIAID), CHD warned about PEG’s known association with adverse immune responses, including life-threatening anaphylaxis.
An estimated 72% of the general population has anti-PEG antibodies (including elevated levels in 8% of Americans) that can set those individuals up for adverse reactions when later exposed to PEG-containing substances.
Pharmaceutical and biotech companies, acutely aware of the correlation between anti-drug antibodies and increased adverse effects, acknowledge that the phenomenon poses a “vexing” and “serious” clinical problem — one that has come into sharp relief as recipients of COVID mRNA injections experience severe allergic reactions.
In light of the interrelationship between PEG and TEG, the planned diffusion of nanoparticle-based TEG in public spaces — including through building heating, ventilation and air conditioning (HVAC) systems — introduces important new questions: Could individuals already sensitized to PEG go into anaphylaxis when they inhale TEG? Or conversely, might people who are exposed to aerosolized TEG then become sensitized to PEG — and run the risk of an adverse reaction when they subsequently encounter a PEG-containing mRNA injection or another “PEGylated” drug?
The newest kid on the block: ‘atmospheric viricides’
The Grignard company describes itself as “an innovative leader in specialty chemical solutions for every industry need,” ranging from precision cleaners and wastewater treatments to “atmospheric effects” for the entertainment industry. In fact, the company’s Grignard FX branch is North America’s “largest producer of theatrical fog and haze fluids” for movies, stadium concerts and theater, as well as being the manufacturer of stage blood promoted as “so realistic they will freak out.”
The company now intends to parlay its extensive theatrical experience into the realm of atmospheric viricides, promising “a light atmospheric haze throughout an indoor space that inactivates enveloped viruses such as the novel coronavirus on non-porous hard surfaces and in the air.”
According to the EPA, the Grignard Pure product has the ability to “permeate and kill. . . over 98 percent of COVID-19 [virus] particles.” Dispersal of Grignard Pure is proposed “via a building’s HVAC system, or using conventional haze/fog machines typically deployed in entertainment venues and in fire training.”
In an example of the revolving regulator-industry door, a four-decade veteran of EPA pesticide regulation is now a leading consultant for Grignard, helping the company market the anti-COVID fluid as the solution to a “critical challenge.”
Meanwhile, outgoing EPA Administrator Andrew Wheeler touted Grignard Pure as a “first-of-its kind” tool to “help fight the spread of the novel coronavirus,” vowing in the agency’s press release that “There is no higher priority for EPA than protecting the health and safety of Americans.”